Cargando…
Efficacy and Safety of AlbisD Compared With Omeprazole 20 mg in Patients With Non-erosive Reflux Disease: A Randomized, Open-label, Active-controlled, Pilot Study
BACKGROUND/AIMS: Proton pump inhibitors (PPIs) are frequently used to treat non-erosive reflux disease (NERD), but their effect is limited. It is not known whether a potential alternative, AlbisD, containing ranitidine hydrochloride, sucralfate hydrate, and tripotassium dicitrato bismuthate, is effe...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Korean Society of Neurogastroenterology and Motility
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6657924/ https://www.ncbi.nlm.nih.gov/pubmed/31327222 http://dx.doi.org/10.5056/jnm18185 |
_version_ | 1783438874115047424 |
---|---|
author | Kim, Eun Jin Lee, Oh Young Lee, Kang Nyeong Lee, Sung Joon Jang, Jae-Young Cho, Jin Woong Kim, Tae-Oh |
author_facet | Kim, Eun Jin Lee, Oh Young Lee, Kang Nyeong Lee, Sung Joon Jang, Jae-Young Cho, Jin Woong Kim, Tae-Oh |
author_sort | Kim, Eun Jin |
collection | PubMed |
description | BACKGROUND/AIMS: Proton pump inhibitors (PPIs) are frequently used to treat non-erosive reflux disease (NERD), but their effect is limited. It is not known whether a potential alternative, AlbisD, containing ranitidine hydrochloride, sucralfate hydrate, and tripotassium dicitrato bismuthate, is effective and safe in treating NERD. The aim of the study is to evaluate the efficacy and safety of AlbisD compared with omperazole in patients with NERD. METHODS: This was a multicenter, randomized, open-label, parallel-group, non-inferiority comparative study. A total of 126 patients with NERD were randomly allocated to either AlbisD twice daily or omeprazole 20 mg once daily for 4 weeks from February 2016 to August 2016. The study patients had histories of heartburn or regurgitation of moderate severity (> score 2) and a frequency of at least 2 episodes per week, and had no mucosal breaks of the esophagus on endoscopy. The primary efficacy variable was complete cure of heartburn at week 4. Secondary efficacy variables evaluating symptoms of heartburn and acid reflux as well as safety profiles were compared in the 2 groups at week 2 and 4 after treatment. RESULTS: A total of 113 patients completed the study (57 and 56 in AlbisD and omeprazole groups, respectively). The proportion of patients with complete cure of heartburn at week 4 was not significantly different between the AlbisD and omeprazole groups (35.1% vs 32.1% respectively, P = 0.740). There were no significant differences between the 2 groups in the any secondary variables including proportions of days without heartburn or acid reflux over 4 weeks (including daytime and nighttime). Adverse events were similarly reported in the 2 groups (7 [12.3%] vs 6 [10.7%]), and there were no serious adverse events. CONCLUSIONS: The efficacy and safety of AlibsD in treating NERD patients are not inferior to those of omeprazole. Therefore, AlbisD can be an alternative to PPIs for NERD. |
format | Online Article Text |
id | pubmed-6657924 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | Korean Society of Neurogastroenterology and Motility |
record_format | MEDLINE/PubMed |
spelling | pubmed-66579242019-07-31 Efficacy and Safety of AlbisD Compared With Omeprazole 20 mg in Patients With Non-erosive Reflux Disease: A Randomized, Open-label, Active-controlled, Pilot Study Kim, Eun Jin Lee, Oh Young Lee, Kang Nyeong Lee, Sung Joon Jang, Jae-Young Cho, Jin Woong Kim, Tae-Oh J Neurogastroenterol Motil Original Article BACKGROUND/AIMS: Proton pump inhibitors (PPIs) are frequently used to treat non-erosive reflux disease (NERD), but their effect is limited. It is not known whether a potential alternative, AlbisD, containing ranitidine hydrochloride, sucralfate hydrate, and tripotassium dicitrato bismuthate, is effective and safe in treating NERD. The aim of the study is to evaluate the efficacy and safety of AlbisD compared with omperazole in patients with NERD. METHODS: This was a multicenter, randomized, open-label, parallel-group, non-inferiority comparative study. A total of 126 patients with NERD were randomly allocated to either AlbisD twice daily or omeprazole 20 mg once daily for 4 weeks from February 2016 to August 2016. The study patients had histories of heartburn or regurgitation of moderate severity (> score 2) and a frequency of at least 2 episodes per week, and had no mucosal breaks of the esophagus on endoscopy. The primary efficacy variable was complete cure of heartburn at week 4. Secondary efficacy variables evaluating symptoms of heartburn and acid reflux as well as safety profiles were compared in the 2 groups at week 2 and 4 after treatment. RESULTS: A total of 113 patients completed the study (57 and 56 in AlbisD and omeprazole groups, respectively). The proportion of patients with complete cure of heartburn at week 4 was not significantly different between the AlbisD and omeprazole groups (35.1% vs 32.1% respectively, P = 0.740). There were no significant differences between the 2 groups in the any secondary variables including proportions of days without heartburn or acid reflux over 4 weeks (including daytime and nighttime). Adverse events were similarly reported in the 2 groups (7 [12.3%] vs 6 [10.7%]), and there were no serious adverse events. CONCLUSIONS: The efficacy and safety of AlibsD in treating NERD patients are not inferior to those of omeprazole. Therefore, AlbisD can be an alternative to PPIs for NERD. Korean Society of Neurogastroenterology and Motility 2019-07 2019-07-30 /pmc/articles/PMC6657924/ /pubmed/31327222 http://dx.doi.org/10.5056/jnm18185 Text en © 2019 The Korean Society of Neurogastroenterology and Motility This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Original Article Kim, Eun Jin Lee, Oh Young Lee, Kang Nyeong Lee, Sung Joon Jang, Jae-Young Cho, Jin Woong Kim, Tae-Oh Efficacy and Safety of AlbisD Compared With Omeprazole 20 mg in Patients With Non-erosive Reflux Disease: A Randomized, Open-label, Active-controlled, Pilot Study |
title | Efficacy and Safety of AlbisD Compared With Omeprazole 20 mg in Patients With Non-erosive Reflux Disease: A Randomized, Open-label, Active-controlled, Pilot Study |
title_full | Efficacy and Safety of AlbisD Compared With Omeprazole 20 mg in Patients With Non-erosive Reflux Disease: A Randomized, Open-label, Active-controlled, Pilot Study |
title_fullStr | Efficacy and Safety of AlbisD Compared With Omeprazole 20 mg in Patients With Non-erosive Reflux Disease: A Randomized, Open-label, Active-controlled, Pilot Study |
title_full_unstemmed | Efficacy and Safety of AlbisD Compared With Omeprazole 20 mg in Patients With Non-erosive Reflux Disease: A Randomized, Open-label, Active-controlled, Pilot Study |
title_short | Efficacy and Safety of AlbisD Compared With Omeprazole 20 mg in Patients With Non-erosive Reflux Disease: A Randomized, Open-label, Active-controlled, Pilot Study |
title_sort | efficacy and safety of albisd compared with omeprazole 20 mg in patients with non-erosive reflux disease: a randomized, open-label, active-controlled, pilot study |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6657924/ https://www.ncbi.nlm.nih.gov/pubmed/31327222 http://dx.doi.org/10.5056/jnm18185 |
work_keys_str_mv | AT kimeunjin efficacyandsafetyofalbisdcomparedwithomeprazole20mginpatientswithnonerosiverefluxdiseasearandomizedopenlabelactivecontrolledpilotstudy AT leeohyoung efficacyandsafetyofalbisdcomparedwithomeprazole20mginpatientswithnonerosiverefluxdiseasearandomizedopenlabelactivecontrolledpilotstudy AT leekangnyeong efficacyandsafetyofalbisdcomparedwithomeprazole20mginpatientswithnonerosiverefluxdiseasearandomizedopenlabelactivecontrolledpilotstudy AT leesungjoon efficacyandsafetyofalbisdcomparedwithomeprazole20mginpatientswithnonerosiverefluxdiseasearandomizedopenlabelactivecontrolledpilotstudy AT jangjaeyoung efficacyandsafetyofalbisdcomparedwithomeprazole20mginpatientswithnonerosiverefluxdiseasearandomizedopenlabelactivecontrolledpilotstudy AT chojinwoong efficacyandsafetyofalbisdcomparedwithomeprazole20mginpatientswithnonerosiverefluxdiseasearandomizedopenlabelactivecontrolledpilotstudy AT kimtaeoh efficacyandsafetyofalbisdcomparedwithomeprazole20mginpatientswithnonerosiverefluxdiseasearandomizedopenlabelactivecontrolledpilotstudy |